Recent Updates
Recently added Catalysts
NKTR Positive Sentiment

Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026

Monday, April 20, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Nektar Therapeutics will host a conference call on April 20, 2026, to discuss the 52-week topline results from the 16-week extension treatment period of its Phase 2b REZOLVE-AA study. The study evaluates rezpegaldesleukin for severe alopecia areata. The results will be shared via a press release and webcast, accessible to interested participants.
Price reaction · baseline $84.86 (2026-04-17 close) · hit pre-market · 4 other NKTR headline(s) in the window, move may be shared
day 0 close · peak
+18.3%
day 1
+15.7%
day 3
+7.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Nektar Therapeutics is advancing its investigational therapy for alopecia areata.
  • The upcoming conference call will provide important topline results.
  • The company is actively engaging with investors and the public.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
10.2%
average across 4 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
Rezpegaldesleukin
Phase 3 · Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

SAN FRANCISCO,April 19, 2026/PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review 52-week topline results from the 16-week extension treatment period of the ongoing Phase 2b REZOLVE-AA clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for severe-to-very-severe alopecia areata on Monday, April 20, 2026 at 8:00 am ET / 5:00 am PT.
Conference CallThe results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at thisLINK.
The event, the press release and the slides will also be available on the events section of the Nektar website athttps://ir.nektar.com/events-and-presentations/events. A replay of the webcast will be available for at least 30 days following the event.
About Nektar TherapeuticsNektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422.
Nektar is headquartered in San Francisco, California. For further information, visitwww.nektar.comand follow us onLinkedIn.
For Investors:
Vivian Wu628-895-0661
Corey Davis, Ph.D.LifeSci Advisors, LLCcdavis@lifesciadvisors.com212-915-2577
Ahu Demir, Ph.D.LifeSci Advisors, LLCademir@lifesciadvisors.com212-915-3820
For Media:

Frequently Asked Questions

What is the purpose of the conference call?

The call will discuss the 52-week topline results from the REZOLVE-AA Phase 2b study.

When will the conference call take place?

The conference call is scheduled for April 20, 2026, at 8:00 am ET.

How can I access the conference call?

Participants can access the live webcast through a link provided by Nektar.

What is rezpegaldesleukin being studied for?

Rezpegaldesleukin is being evaluated for treating severe-to-very-severe alopecia areata.

ShareAdd on Google
Tags: NKTR Viatris Investor Conferences Healthcare Nektar Therapeutics rezpegaldesleukin alopecia areata Phase 2b clinical trial
Last updated: Apr 20, 2026

Biotech snapshot

Cash runway
$1023M liquidity · $25M/mo burn
~40 mo
Minimal dilution risk
Lead asset
RezpegaldesleukinPhase 3
Moderate-to-Severe Atopic Dermatitis →

Catalyst track record

+186%
best trade around NKTR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for NKTR.

See every catalyst's timing & PoA →